• "Loss of Bone Signal" on 99m Tc-Labeled Pyrophosphate Scintigraphy in a Patient With Wild-Type Transthyretin Amyloidosis
• 99mTc-PYP and 68Ga-FAPI PET/CT Images of Hereditary Transthyretin Amyloidosis With Cardiac Involvement
• A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
• Acoramidis in Transthyretin Amyloid Cardiomyopathy
• Acoramidis in Transthyretin Amyloid Cardiomyopathy. Reply
• Addressing Health Disparities-The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger
• Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program
• Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings
• Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis
• Amyloid Typing in Cardiac Amyloidosis Using Western Blotting
• Amyloïdose héréditaire à transthyrétine accompagnée d’un syndrome du canal carpien
• Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
• Assessment of incidental cardiac uptake in bone scintigraphy across Spain: The ECCINGO study
• Atrial fibrillation in the setting of cardiac amyloidosis - A review of the literature
• ATTRv-V30M Type A amyloid fibrils from heart and nerves exhibit structural homogeneity
• Bilateral Multiple Fractures Obstruct Quantitation of 99m Tc-Pyrophosphate Imaging for Cardiac Amyloidosis
• Cardiac amyloidosis : simplifying the diagnosis of a complex disease
• Cardiac amyloidosis and aortic stenosis: what do we know?
• Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy
• Cardiopulmonary exercise testing in transthyretin amyloid cardiomyopathy patients: a long-term follow-up study
• Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker
• Carpal Tunnel Syndrome and Transthyretin Amyloidosis in the All of Us Research Program
• Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)
• Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study
• Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report
• Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia
• Clinicopathological Features of Amyloid Neuropathy: A Four Decade Experience
• Cryo-EM confirms a common fibril fold in the heart of four patients with ATTRwt amyloidosis
• Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis
• Deep Learning-Enabled Quantification of ^99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis
• Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype
• Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician
• Detection of Circulating Transthyretin Amyloid Aggregates in Plasma: A Novel Biomarker for Transthyretin Amyloidosis
• Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study
• Disentangling Knots of Misfolded Proteins: Do We Really Know the Prognostic Implications of the Pathogenic V122I TTR Variant?
• Distinctive Deposition Patterns of Sporadic Transthyretin-Derived Amyloidosis in the Atria: A Forensic Autopsy-Based Study
• Double pathogenic variant in an ATTRv patient with mixed phenotype
• Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible?
• Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy
• Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
• Efficacy of Computed Tomography-Based Evaluation of Myocardial Extracellular Volume Combined With Red Flags for Early Screening of Concealed Cardiac Amyloidosis in Patients With Atrial Fibrillation
• Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study
• Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy
• Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study
• Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update
• Hereditary Transthyretin Amyloidosis (hATTR) with Polyneuropathy Clusters Are Located in Ancient Mining Districts: A Possible Geochemical Origin of the Disease
• Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling
• Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry
• Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis
• Identification of the interfacial regions in misfolded transthyretin oligomers
• Inverse correlation between age of onset and myocardial amyloid deposition quantified by (99m)Tc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy
• Late-onset familial amyloidosis polyneuropathy associated with c.186G>C in transthyretin
• Letter to the editor concerning "Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?"
• Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy
• Mimicking kidney flow shear efficiently induces aggregation of LECT2, a protein involved in renal amyloidosis
• Mispacking of the F87 sidechain drives aggregation-promoting conformational fluctuations in the subunit interfaces of the transthyretin tetramer
• Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils
• Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality
• Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis
• Nuclear imaging techniques for cardiac amyloidosis
• Olpasiran Pharmacodynamic Study: Ensuring We Go a Mile Deep But More Than an Inch Wide
• Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World Data
• Palinacousis in amyloidosis: exploring the hallucinatory phenomenon in brain pathology-a case report
• Paraproteinemic neuropathies
• Pathological evaluation of the pathogenesis of diabetes mellitus and diabetic peripheral neuropathy
• Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis
• Prevalence of moderate-severe aortic stenosis in patients with cardiac amyloidosis in a referral center
• Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis
• Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia
• Prognostic Value of [(99m)Tc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function
• Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis
• Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy
• Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro
• Recent insights into haematology and peripheral nerve disease
• Regional Distribution of Extracellular Volume Quantified by Cardiac CT in Aortic Stenosis: Insights Into Disease Mechanisms and Impact on Outcomes
• Renal tubular acidosis in hereditary transthyretin amyloidosis (ATTRv)
• Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval
• Scintigraphic and Echocardiographic Study of Patients with Pathogenic or Probably Pathogenic Variants of the TTR Gene without Overt Cardiac Involvement
• Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment
• SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
• Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review
• Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety
• Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis
• Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones
• Teaching NeuroImage: Scalloped Pupils in a Transplant Patient With Hereditary Transthyretin Amyloidosis
• Temporal implementation of a regional referral pathway in transthyretin cardiac amyloidosis: Emilia-Romagna experience
• The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium-glucose cotransporter 2 inhibitors?
• The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction
• The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis
• Thromboembolic and bleeding risk in cardiac amyloidosis
• Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score
• Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019)
• Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis
• Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study
• Treatment of transthyretin cardiac amyloidosis
• Turning Meters Into Years: Walking to Survive Transthyretin Cardiac Amyloidosis
• Ultrasensitive Proteomics of Trace Cardiac Tissues with Anchor-Nanoparticles
• Unravelling transthyretin cardiac amyloidosis: updates on diagnosis, treatment, and prevalence insights
• Update in 'wild-type' transthyretin cardiac amyloidosis: Clinical guide for its diagnosis and treatment
• Value of multi-modality small fiber assessments in a genotypically diverse cohort of transthyretin-related amyloidosis in the early stages of disease